WHO committee recommend transfer of Tamiflu from the Core to the Complementary Essential   Medicines List “and its use be restricted to severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients” because “there now exists additional evidence of oseltamivir in seasonal and pandemic flu which has reduced the previously estimated magnitude of effect of oseltamivir on relevant clinical outcomes”.

http://www.who.int/selection_medicines/committees/expert/21/en/

http://www.who.int/selection_medicines/committees/expert/21/eml21applications/en/

http://www.who.int/selection_medicines/committees/expert/21/applications/oseltamivir_del/en/